Latest Articles
-
Forecast Of The Day: Merck’s Oncology Drug Sales
What? Trefis expects Merck (NYSE:MRK) Oncology drug sales to grow from levels of around $16 billion in 2020 to $19 billion in 2021 and $22 billion in 2022. Why? We expect growth to come on the back of higher sales of Merck’s immensely p...
-
What’s Next For Merck Stock After A 5% Drop Following Q1 Miss?
[Updated: 4/30/2021] Merck Stock Decline The stock price of Merck (NYSE:MRK) has seen a 5.5% drop over the last five trading days, after the company announced Q1 results that came in below the street estimates. Merck’s Q1 revenue of $12.1 billi...
-
Earnings Beat In Cards For Merck’s Q1?
Merck (NYSE: MRK) is scheduled to report its Q1 2021 results on Thursday, April 29. We expect the company to likely post revenue and earnings above the consensus estimates, led by continued expansion of Keytruda, and a recovery in the companyR...
-
Merck Stock Remains Significantly Undervalued At $77
Merck (NYSE: MRK) looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compar...
-
Merck Q4 Earnings Preview: Keytruda And Gardasil In Focus
Merck (NYSE: MRK) is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, s...
-
What’s Happening With Merck Stock?
[Updated 12/2/2020] Merck Update Merck (NYSE: MRK) recently announced that it has sold its equity investment in Moderna. Merck has benefited from a whopping 7x surge in Moderna stock this year, given its Covid-19 vaccine development. Though, de...
-
Forecast of the Day: Merck’s Oncology Drugs Sales
The FDA has approved Merck’s (NYSE: MRK) Keytruda (pembrolizumab), combined with chemo, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. This ad...
-
Merck Stock Poised For 25% Gains
Merck’s stock (NYSE: MRK) lost more than 28% – dropping from $92 at the beginning of the year to $66 in late March – then jumped 21% to around $80 now. That means it has partially recovered to the levels where it started the year. That ...
-
Should You Buy Merck Stock At $85?
After a 28% rise since the March 23 lows of this year, at the current price of around $85 per share we believe Merck’s stock (NYSE: MRK) looks attractive and it has more room for growth. MRK stock has moved from $66 to $85 off the recent bottom c...
-
Consider Buying Merck Over Johnson & Johnson’s Stock
Johnson & Johnson’s stock (NYSE:JNJ) has gained 38% since the March 23 lows of this year, while Merck’s stock (NYSE:MRK) has slightly underperformed and gained 30% of its value. The lockdown in various parts of the world has had a nega...
-
Eli Lilly Stock Is Trending But Is Merck Better?
Merck’s stock (NYSE:MRK) has declined by close to 10% since early February after the WHO declared the coronavirus a global health emergency, while Eli Lilly stock (NYSE:LLY) has fared much better and gained 15%. The lockdown in various par...
-
Merck Over Roche For 25% Gains?
Two pharmaceutical giants – Merck (NYSE:MRK) and Roche (OTCMKTS:RHHBY) – have seen their stock price grow over 20% since March 23 lows, significantly underperforming the broader markets, which rallied over 40% through June 5 from the ...
-
Merck’s Stock Headed To $100?
Merck’s stock (NYSE:MRK) has underperformed the broader markets as well as some of its peers over the last few weeks. While Merck’s stock grew 20% since the recent lows of March 23, the S&P 500 gained 26%. Looking at other pharmac...
-
After Allergan Acquisition Is AbbVie A Better Buy Compared To Merck?
The pharmaceutical companies have not been immune to the current coronavirus crisis, although they have fared much better than the broader markets. While Merck’s (NYSE:MRK) stock has declined 9% since early February, after the WHO declared ...
-
Despite Outperforming The Broader Markets, Merck Appears To Be Oversold At $80
Merck (NYSE:MRK) stock declined 10% from $90 levels in the beginning of this year to $80 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Merck’s stock has marginally outperformed the broader markets, we believe...
